Dabur says India business is unaffected by USFDA warning at Silvassa plant
Dabur said its Silvassa pharmaceutical facility remains operational despite a USFDA warning citing CGMP and data-integrity deficiencies. The company is implementing corrective actions, has shifted some production to Baddi and says the issue does not affect its India business.
Dabur said its India business is unaffected by a USFDA warning over CGMP and data-integrity deficiencies at its Silvassa pharmaceutical plant. The facility remains operational, with some production shifted to Baddi, while Dabur implements corrective actions and addresses US import restrictions.
Why this matters
The warning follows Dabur’s disclosure that the Silvassa issue was limited to private-label exports, as the company targets double-digit FY27 growth and challenges FSSAI’s ban on “100%” claims in Delhi High Court.
Retail-company signals are accelerating, up 89,518% QoQ.
Also reported by
- Mint · Companies — Same time